IL18 and age-related macular degeneration: Treatment with PU-91 altered the gene expression of inflammatory markers, IFNB1 (25% decrease; p=0.03; AMD UN: 1 ± 0.08, n=4; AMD PU-91: 0.75 ± 0.02, n=4) (Figure 6A), IL-18 (56% decrease; p=0.03; AMD UN: 1 ± 0.13, n=4; AMD PU-91: 0.44 ± 0.12, n=4) (Figure 6B), and of a complement inhibitor CFH (106% increase; p=0.03; AMD UN: 1 ± 0.07, n=4; AMD PU-91: 2.06 ± 0.21, n=3) (Figure 6C).